Present review highlights various drug delivery systems used for delivery of pharmaceutical
agents mainly antibiotics, antineoplastic agents, neuropeptides, and other therapeutic …

Ischemic stroke is a disease with high morbidity and mortality worldwide, which often places
an additional strain on families and society due to the poor prognosis. Blood brain-barrier …

Most of the successes in experimental models of stroke have not translated well to the clinic.
One potential reason for this failure is that stroke mainly afflicts the elderly and the majority of …

Bryostatin 1, a potent activator of protein kinase C epsilon (PKCɛ), has been shown to
reverse synaptic loss and facilitate synaptic maturation in animal models of Alzheimer's …

Tissue plasminogen activator (tPA) is the only therapeutic agent approved to treat patients
with acute ischemic stroke. The clinical benefits of tPA manifest when the agent is …

To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard
treatment for ischemic stroke. However, when tPA is given beyond 4.5 hours of stroke onset …

Ischemic stroke and Alzheimer's disease (AD), despite being distinct disease entities, share
numerous pathophysiological mechanisms such as those mediated by inflammation …

The central nervous system (CNS) is the most complex system in human body, and there is
often a lack of effective treatment strategies for the disorders related with CNS. Natural …

Tissue plasminogen activator (tPA) thrombolysis continues to be the gold standard therapy
for ischemic stroke. Due to the time-limited treatment window, within 4.5 h of stroke onset …

Abstract Background/Aims: Enriched environment (EE) has been reported to exert
neuroprotective effect in animal models of ischemic stroke. However, the underlying …